X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (39) 39
humans (35) 35
oncology (33) 33
cancer (28) 28
male (27) 27
middle aged (27) 27
female (24) 24
adult (23) 23
aged (23) 23
metastasis (17) 17
chemotherapy (13) 13
tumors (13) 13
life sciences (12) 12
treatment outcome (12) 12
aged, 80 and over (11) 11
antineoplastic agents - therapeutic use (11) 11
thyroid neoplasms - drug therapy (11) 11
prognosis (10) 10
carcinoma (9) 9
disease-free survival (9) 9
medical prognosis (9) 9
sorafenib (9) 9
survival (9) 9
survival analysis (9) 9
thyroid cancer (9) 9
thyroid neoplasms - pathology (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
care and treatment (8) 8
cisplatin (8) 8
clinical trials (8) 8
colorectal cancer (8) 8
retrospective studies (8) 8
5-fluorouracil (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
cancer therapies (7) 7
kaplan-meier estimate (7) 7
metastases (7) 7
mutation (7) 7
neoplasm metastasis (7) 7
papillary (7) 7
patients (7) 7
therapy (7) 7
adenocarcinoma (6) 6
endocrinology & metabolism (6) 6
gemcitabine (6) 6
management (6) 6
multicenter (6) 6
phase-ii trial (6) 6
surgery (6) 6
young adult (6) 6
abridged index medicus (5) 5
adenocarcinoma, follicular - drug therapy (5) 5
analysis (5) 5
antineoplastic agents - adverse effects (5) 5
camptothecin - administration & dosage (5) 5
camptothecin - analogs & derivatives (5) 5
colorectal neoplasms - drug therapy (5) 5
colorectal neoplasms - pathology (5) 5
diagnosis (5) 5
drug therapy (5) 5
fluorouracil (5) 5
genetics (5) 5
hematology, oncology and palliative medicine (5) 5
oxaliplatin (5) 5
pancreatic neoplasms - pathology (5) 5
phenylurea compounds - therapeutic use (5) 5
solid tumors (5) 5
sunitinib (5) 5
thyroid neoplasms - mortality (5) 5
adenocarcinoma - drug therapy (4) 4
adenocarcinoma - pathology (4) 4
adenocarcinoma - secondary (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
biomarkers (4) 4
cancer research (4) 4
cetuximab (4) 4
combination (4) 4
deoxycytidine - analogs & derivatives (4) 4
docetaxel (4) 4
double-blind (4) 4
fluorouracil - administration & dosage (4) 4
human health and pathology (4) 4
indoles - therapeutic use (4) 4
irinotecan (4) 4
leucovorin (4) 4
metastatic colorectal cancer (4) 4
organoplatinum compounds - administration & dosage (4) 4
pancreas (4) 4
pancreatic neoplasms - drug therapy (4) 4
phenylurea compounds - administration & dosage (4) 4
pyrroles - therapeutic use (4) 4
radiation therapy (4) 4
regorafenib (4) 4
research (4) 4
studies (4) 4
thyroid carcinoma (4) 4
toxicity (4) 4
trial (4) 4
1st-line treatment (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 757 - 765
Abstract Background Antitumor activity of molecular-targeted agents is guided by the presence of documented genomic alteration in specific histological... 
precision medicine | molecular-targeted agents | advanced cancer | decision-making | molecular profiling | MULTICENTER | GENOMICS | ONCOLOGY | MEDICINE | Life Sciences
Journal Article
Targeted Oncology, ISSN 1776-2596, 2/2016, Volume 11, Issue 1, pp. 123 - 125
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1817 - 1825
In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more... 
PHASE-III TRIAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | CLINICAL-TRIALS | IRINOTECAN | OXALIPLATIN | 1ST-LINE THERAPY | COMBINATION | CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Severity of Illness Index | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Quality of Life | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Chemotherapy, Combination | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Leucovorin | Comparative analysis | Drug therapy | Fluorouracil | Clinical trials | Cytotoxicity | Pancreas | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 819 - 828
Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | MULTICENTER | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | GALLBLADDER | COMBINATION | TUMORS | CHEMOTHERAPY | GALL-BLADDER CANCER | ras Proteins - genetics | Peripheral Nervous System Diseases - chemically induced | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Oxaliplatin | Common Bile Duct Neoplasms - drug therapy | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Cetuximab | Neutropenia - chemically induced | Common Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Aspartate Aminotransferases - blood | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Cholangiocarcinoma - genetics | Carcinoma - genetics | Aged | Mutation | Deoxycytidine - analogs & derivatives | Chemotherapy | Product development | Gemcitabine | Comparative analysis | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 23, pp. 2189 - 2197
Journal Article
Future Oncology, ISSN 1479-6694, 09/2018, Volume 14, Issue 22, pp. 2239 - 2246
Regorafenib is an orally available multikinase inhibitor, currently approved in metastatic chemorefractory colorectal cancer patients. The results of two large... 
regorafenib adverse events | anti-angiogenic treatment | adherence to oral treatment | late lines of treatment | metastatic colorectal cancer | regorafenib | tyrosine-kinase inhibitor | targeted treatment | MULTICENTER | METABOLITES | MANAGEMENT | KINASE INHIBITORS | SORAFENIB | INDUCED HYPOTHYROIDISM | BAY 73-4506 | STRATEGIES | START LOW | ONCOLOGY | PLUS
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2015, Volume 113, Issue 7, pp. 989 - 995
Journal Article
The Lancet, ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 319 - 328
Background Patients with radioactive iodine (131I)-refractory locally advanced or metastatic diff erentiated thyroid cancer have a poor prognosis because of... 
Journal Article
The oncologist, ISSN 1083-7159, 06/2019, p. theoncologist.2018-0786
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall survival (OS) of between 8 and 11 months. However, a... 
Journal Article
TARGETED ONCOLOGY, ISSN 1776-2596, 02/2016, Volume 11, Issue 1, pp. 123 - 125
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s11523-015-0407-4 
ONCOLOGY | INHIBITOR | COLORECTAL-CANCER | BAY 73-4506 | Pyridines - adverse effects | Pyridines - administration & dosage | Drug Administration Schedule | Phenylurea Compounds - administration & dosage | Phenylurea Compounds - adverse effects | Colorectal Neoplasms - drug therapy | Humans
Journal Article